Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer
复制标题
DOI：
10.1093/annonc/mdm004
复制
发表时间：
2007-05-01
影响因子：
50.5
通讯作者：
Kelsen, D. P.
中科院分区：
文献类型：
--
作者：
Ilson, D. H.;Wadleigh, R. G.;Kelsen, D. P.
背景资料：本研究的目的是评估每周紫杉醇（Taxol）在晚期食管癌中的疗效。患者和方法：102例晚期食管癌患者接受紫杉醇80 mg/m2每周1小时输注治疗。一个周期定义为治疗4周。95例患者可评估毒性，86例完成至少2个周期治疗的患者可评估缓解。66例患者腺癌（66%）和65例（68%）没有以前的化疗。结果：中位数为3个周期（范围1-11）。在11例患者中观察到部分缓解（PIPS）[13%，95%置信区间（CI）6%-20%]。在既往未接受过化疗的患者中，10例患者（15%，95% CI 6%-24%）出现PR，腺癌（8/50，16%）和鳞癌（2/15，13%）的缓解率相当。在既往化疗患者中观察到有限缓解（1/21，5%）。中位缓解持续时间为172天。中位生存期为274天。治疗耐受性良好，血液学或3级或4级毒性最小。结论：每周紫杉醇对食管癌的活性有限。中位生存期、中等活性和治疗耐受性表明，对于不能耐受联合化疗的患者，每周紫杉醇可能是一种选择。
Background: The purpose of the study was to evaluate the efficacy of weekly paclitaxel (Taxol) in advanced esophageal cancer.Patients and methods: One hundred and two patients with advanced esophageal cancer were treated with paclitaxel 80 mg/m(2) weekly over a 1-h infusion. One cycle was defined as 4 weeks of therapy. Ninety-five patients were assessable for toxicity and 86 patients who completed at least two cycles of treatment were assessable for response. Sixty-six patients had adenocarcinoma (66%) and 65 patients (68%) had no prior chemotherapy.Results: A median of three cycles was delivered (range 1-11). Partial responses (PIPS) were seen in 11 patients [13%, 95% confidence interval (CI) 6% to 20%]. In patients without prior chemotherapy, PRs were seen in 10 patients (15%, 95% Cl 6% to 24%), with comparable response in adenocarcinoma (8/50, 16%) and squamous carcinoma (2/15, 13%). Limited response was seen in patients with prior chemotherapy (1/21, 5%). The median duration of response was 172 days. The median survival was 274 days. Therapy was well tolerated with minimal hematologic or grade 3 or 4 toxicity.Conclusion: Weekly paclitaxel has limited activity in esophageal cancer. The median survival, modest activity, and tolerance of therapy indicate that weekly paclitaxel may be an option in patients unable to tolerate combination chemotherapy.